Deferred
Showing 1 to 2 of 2
| Title | Deferred ID | Guidance programme | Deferred date |
|---|---|---|---|
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5] | D5 | Technology appraisal guidance | |
| Teprotumumab for treating thyroid eye disease [ID6432] | D1 | Technology appraisal guidance |